790. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam
Session: Poster Abstract Session: Treatment of Resistant Infections - Clinical Analyses
Thursday, October 5, 2017
Room: Poster Hall CD
  • IDweek 2017 Poster.pdf (429.9 kB)
  • Background: CRE is an urgent threats to public health with a high mortality estimated at >30-50%. Until recently, polymyxin-based antibiotics were the only available options. However, a new therapeutic option has become available: ceftazidime-avibactam. We sought to describe outcomes from these infections treated with ceftazidime-avibactam.

    Methods: From 9/2015 to 12/ 2016, we reviewed charts of 11 patients infected with CRE who received ceftazidime-avibactam at USC (Los Angeles, CA). Sixteen isolates analyzed. All isolates were resistant to meropenem (MIC ≥ 16). Carbapenemase production confirmed by detection of blaKPC. Clinical success defined as clinical improvement, lack of recurrence, and survival in 90 days. Recurrence defined as clinical signs of infection and recovery of CRE after 7 days of treatment.

    Results: The median age was 49 (35-89); 73% (7/11) female; and 27% (3/11) solid organ transplants. All CRE infections caused by Klebsiella pneumoniae. All sequence type 258, 7/11 harboring blaKPC-2 and 4/11 blaKPC-3. Nine capsular type wzi-154 and 2 wzi-29. qSOFA score was 0 (0-2) predicting mortality of 3%. Seven had intraabdominal infections; 2 pyelonephritis, 1 skin and soft tissue infection, and 1 primary bacteremia. There were five episodes of secondary bacteremia. The patients were treated for a median duration of 15 (3-43) days. All received other antibiotics prior to ceftazidime-avibactam. 87% (9/11) treated with monotherapy and 13% (2/11) in conjunction with colistemethate sodium. 27% (3/11) were receiving CRRT or hemodialysis during treatment. No incidents of renal toxicity observed using RIFLE criteria. Clinical success was 73% (8/11); 30 day survival rate 82% (9/11); 90 day survival rate 73% (8/11); and in hospital mortality 27% (3/11). Patients receiving CRRT or hemodialysis had 75% (3/4) mortality (P=0.02). Recurrence occurred in 18% (2/11). Decreased sensitivity to ceftazidime-avibactam noted in one patient. 27% (3/11) had CRE isolated after 7 days treatment.

    Conclusion: In CRE-infected patient treated with ceftazidime-avibactam, the overall mortality rate was 27% with the highest mortality among those receiving renal replacement therapy which was comparable to a prior studies. Additional research is needed to optimize use of ceftazidime-avibactam to treat CRE infections.

    Elham Rahmati, M.D.1, Emily Blodget, M.D.1, Rosemary C. She, M.D.2, Jennifer Cupo Abbott, PharmD3, Robert A. Bonomo, MD4 and Brad Spellberg, M.D.1, (1)Infectious Diseases, USC+LAC Medical Center, Los Angeles, CA, (2)Pathology, Keck School of Medicine of USC, Los Angeles, CA, (3)Pharmacy, USC+LAC, Los Angeles, CA, (4)Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH


    E. Rahmati, None

    E. Blodget, None

    R. C. She, None

    J. Cupo Abbott, None

    R. A. Bonomo, None

    B. Spellberg, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.